Intercept Pharmaceuticals
22 clinical trials · Sponsor
◉ Watch Intercept Pharmaceuticals
| Record | Firm | Date |
|---|---|---|
| To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate (NCT06488911) | Intercept Pharmaceuticals | 2024-07-01 |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (NCT05639543) | Intercept Pharmaceuticals | 2022-12-15 |
| A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (NCT05293938) | Intercept Pharmaceuticals | 2022-03-28 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC (NCT04594694) | Intercept Pharmaceuticals | 2019-10-02 |
| Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (NCT03633227) | Intercept Pharmaceuticals | 2018-06-22 |
Track Intercept Pharmaceuticals automatically
Every clearance here is in the API, with alerts when new ones post.